Our team at the discoveric bio group has a track record in drug development and commercialization from biotech and Big Pharma. Our expertise goes from discovery through pre-clinical and clinical development into commercial excellence.
We collaborate with a wide network of world class experts and CROs to develop and advance our pipeline in Alzheimer’s Disease and Antimicrobial Resistance.
The discoveric bio group currently comprises three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. We employ bi- and multi-specific, truly natural IgG antibody technologies.
Each of these companies is working independently on one or more antibody therapeutic projects.
Oliver is a co-founder of the discoveric bio group and serves as the CEO.
Jean-Philippe is a Neuroscientist development specialist and serves as CSO to discoveric bio alpha and discoveric bio gamma.
Philipp is an antimicrobial development specialist and serves as CSO to discoveric bio beta.
Dr. Erich Hunziker is the founder and Chairman of the Board of discoveric bio group.
